Company Encyclopedia
View More
name
Jet Bio-Filtration
688026.SH
Guangzhou Jet Bio-Filtration Co., Ltd. researches, develops, manufactures, and sells laboratory consumable products. Its products include bioprocess, cell culture, liquid handling and storage, filtration products, molecular biology, cellsafe, medical consumables, biological reagents, laboratory equipment, petri dishes, ELISA plates, immuno micro plates, inoculating loops and needles, cuvettes, latex powder-free gloves, NBR gloves, and other products. The company was founded in 2001 and is headquartered in Guangzhou, China.
354.40 B
688026.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking34/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.60%C
    • Profit Margin14.01%B
    • Gross Margin43.65%B
  • Growth ScoreB
    • Revenue YoY7.96%B
    • Net Profit YoY11.75%C
    • Total Assets YoY7.19%B
    • Net Assets YoY6.52%B
  • Cash ScoreB
    • Cash Flow Margin713.56%B
    • OCF YoY7.96%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreB
    • Gearing Ratio28.75%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jet Bio-Filtration released its performance for the first three quarters, with a net profit attributable to the parent company of 57.29 million yuan, a year-on-year increase of 14.22%

    According to the Zhitong Finance APP, Jet Bio-Filtration disclosed its third-quarter report for 2025. The company achieved revenue of 398 million yuan in the first three quarters, a year-on-year increase of 1.88%; net profit attributable to the parent company was 57.29 million yuan, a year-on-year increase of 14.22%; net profit excluding non-recurring items was 53.16 million yuan, a year-on-year increase of 20.71%; basic earnings per share were 0.42 yuan

    Zhitong·
    SH
    688026
    +0.98%
    Zhitong·
    SH
    688026
    +0.98%

    Jet Bio-Filtration: Plans to invest 25 million yuan in establishing an industrial fund, has completed the filing

    Jet Bio-Filtration announced that the company reviewed and approved a proposal to establish an industrial fund for external investment on July 3, 2025, in collaboration with Nanyue Aoyang and Nanyue Fund to initiate the establishment of Nantou Investment, which will primarily invest in early and mid-stage biopharmaceutical projects. The total investment amount of the industrial fund is 50.01 million yuan, with the company as a limited partner subscribing 25 million yuan, accounting for 49.99%. Recently, Nantou Investment has completed the filing procedures with the Asset Management Association of China and obtained the "Private Investment Fund Filing Certificate."

    Zhitong·
    SH
    688026
    +0.98%
    Zhitong·
    SH
    688026
    +0.98%

    The medical consumables sector has undergone significant adjustments, with SINOMED hitting the limit down

    The medical consumables sector has undergone significant adjustments, with SINOMED hitting the limit down, and Tianyi Medical, Double Medical, Guoke Hengtai, ZHYL, Jet Bio-Filtration, and NANFANG MEDICAL also following suit

    Zhitong·
    SZ
    301097
    -4.31%
    SZ
    002901
    -1.15%
    SH
    688108
    -3.09%
    Zhitong·
    SZ
    301097
    -4.31%
    SZ
    002901
    -1.15%
    SH
    688108
    -3.09%

    Jet Bio-Filtration: Securities Affairs Representative Xing Wanfang resigned for personal reasons

    Jet Bio-Filtration announced that the company's board of directors recently received a written resignation letter from Ms. Xing Wanfang, the representative for securities affairs. Ms. Xing Wanfang has resigned from her position as the representative for securities affairs for personal reasons and will no longer hold any position in the company after her resignation. The work she was responsible for has been handed over, and her resignation will not affect the normal progress of the company's related work

    Zhitong·
    SH
    688026
    +0.98%
    Zhitong·
    SH
    688026
    +0.98%

    Jet Bio-Filtration: The industrial fund has completed business registration

    Jet Bio-Filtration announced that the Guangzhou Zengcheng Nante Biomedical Investment Partnership, co-funded by the company, Guangzhou Nanyue Aoyang Fund Management Co., Ltd., and Guangzhou Nanyue Fund Group Co., Ltd., has completed the business registration procedures and obtained the "Business License" issued by the Market Supervision Administration of Zengcheng District, Guangzhou. The total investment amount of the industrial fund is RMB 50.01 million, with Jet Bio-Filtration as a limited partner contributing RMB 25 million, accounting for 49.99% of the subscribed capital. The industrial fund primarily invests in early and mid-stage biomedical projects

    Zhitong·
    SH
    688026
    +0.98%
    Zhitong·
    SH
    688026
    +0.98%